

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

847

CHEMOTHERAPY OF LEPROSY

Report of a
WHO Study Group



World Health Organization

Geneva 1994

WHO Library Cataloguing in Publication Data

WHO Study Group on Chemotherapy of Leprosy

Chemotherapy of leprosy : report of a WHO study group.

(WHO technical report series ; 847)

1. Leprosy – drug therapy I. Title II. Series

ISBN 92 4 120847 3

(NLM Classification: WC 335)

ISSN 0512-3054

The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

© World Health Organization 1994

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

Printed in Switzerland

94/10091 – Benteli – 8000

Contents

1. Introduction	1
1.1 WHO Study Group on Chemotherapy of Leprosy for Control Programmes, 1981	1
2. The present situation	2
2.1 Experience with multidrug therapy (MDT) since 1981	3
2.1.1 MDT for paucibacillary leprosy	4
2.1.2 MDT for multibacillary leprosy	5
2.1.3 Toxic and lepra reactions during MDT	7
2.2 Drug resistance	7
2.3 Persistence of <i>Mycobacterium leprae</i>	8
2.4 Immunotherapy	8
2.5 Lepra reactions	8
3. Currently available antileprosy drugs	8
3.1 Dapsone	9
3.2 Rifampicin	9
3.3 Clofazimine	9
3.4 Thioamides (ethionamide and prothionamide)	10
3.5 Fluoroquinolones	10
3.6 Minocycline	10
3.7 Macrolides	11
3.8 Other drugs	11
4. Recommended chemotherapeutic regimens	12
4.1 Multibacillary leprosy	12
4.2 Paucibacillary leprosy	12
4.3 Alternative MDT regimens	13
4.3.1 Rifampicin resistance or toxicity	13
4.3.2 Severe dapsone toxicity	13
4.3.3 Refusal to accept clofazimine	13
5. Operational aspects	14
5.1 Classification	14
5.2 Laboratory facilities	14
5.2.1 Facilities for bacteriological examination	14
5.2.2 Referral facilities for mouse-footpad studies	14
5.2.3 Other laboratory facilities	15
5.3 Re-treatment of multibacillary cases previously treated only with dapsone monotherapy	15
5.4 Drug delivery	15
5.5 Management of reactions and prevention of deformity	16
5.6 Follow-up after completion of therapy	17
5.7 Health education and medical care	17
5.8 Household contacts of patients	17
5.9 Training	17
5.10 Drugs and drug supplies	18
5.11 Planning and human and financial resources	18
5.12 Monitoring and evaluation	18
5.13 Treatment of patients with human immunodeficiency virus (HIV) infection or tuberculosis	19

6. Research trends and needs	19
6.1 New bactericidal drugs	19
6.2 Shorter therapy	20
6.3 Intermittent supervised therapy	20
6.4 Improved reaction therapy	20
Acknowledgements	20
References	21

WHO Study Group on Chemotherapy of Leprosy

Geneva, 1–5 November 1993

Members*

- Dr M. Becx-Bleumink, Senior Tuberculosis Consultant, Royal Netherlands Tuberculosis Association, The Hague, Netherlands (*Chairman*)
- Dr Y. Hasibuan, Chief, Leprosy Control Division, Directorate-General, Communicable Disease Control and Environmental Health, Jakarta, Indonesia
- Dr R. Jacobson, Director, Gillis W. Long Hansen's Disease Center, Carville, LA, USA (*Rapporteur*)
- Dr H. J. S. Kawuma, Director, St Francis Leprosy Centre, Jinja, Uganda
- Professor Li Huan-Ying, Leprosy Unit, Beijing Tropical Medicine Research Institute, Beijing, China (*Vice-Chairman*)
- Dr B. Mittal, Deputy Director-General (Leprosy), Directorate General of Health Services, New Delhi, India
- Dr D. V. A. Opromolla, Director, Lauro de Souza Lima Institute, Bauru, Brazil
- Dr M. F. R. Waters, Consultant Leprologist, Hospital for Tropical Diseases, London, England
- Dr Y. Yuasa, Executive and Medical Director, Sasakawa Memorial Health Foundation, Tokyo, Japan

Secretariat

- Dr R. Ganapati, Director, Bombay Leprosy Project, Bombay, India (*Temporary Adviser*)
- Professor L. Levy, Department of Dermatology, Hadassah Medical Organization, Jerusalem, Israel (*Temporary Adviser*)
- Dr S. K. Noordeen, Chief Medical Officer, Leprosy Control, Division of Control of Tropical Diseases, WHO, Geneva, Switzerland (*Secretary*)

* Unable to attend: Dr T. Chiang, Chief Executive, Marie Adelaide Leprosy Centre, Karachi, Pakistan; Professor J. Grosset, Faculty of Medicine, Pitié-Salpêtrière Hospital, Paris, France.

1. **Introduction**

A WHO Study Group on Chemotherapy of Leprosy met in Geneva from 1 to 5 November 1993. Opening the meeting on behalf of the Director-General, Dr S. K. Noordeen, Chief Medical Officer, Leprosy Control, recalled that a WHO Study Group on Chemotherapy of Leprosy for Control Programmes had recommended the introduction of multidrug therapy (MDT) for leprosy in 1981, at a time when global efforts to control the disease were meeting with little success, owing to the widespread occurrence of dapsone resistance. Describing this as a bold and balanced decision, Dr Noordeen noted that the critical role of MDT in the successful control of the disease was now well recognized.

Some 4.3 million patients had already been cured through MDT¹ and the number of cases of leprosy had been reduced by two-thirds. Efforts still had to be made, however, to simplify the administration of MDT, to improve accessibility for patients with special needs (e.g. those living in remote areas), and to derive the maximum benefit from the new antileprosy drugs. Even though leprosy could be successfully controlled through chemotherapy, it was important to monitor the situation constantly for problems such as drug resistance and to develop even more effective drug combinations.

The objectives of the present Study Group were as follows:

- To review the information collected since 1981 (the year when the WHO MDT regimens were introduced) and to recommend any modifications of these regimens that seemed appropriate in the light of the data collected.
- To make recommendations regarding the use of the new antileprosy drugs in the chemotherapy of leprosy.
- To make recommendations regarding changes in the operational aspects of chemotherapy of leprosy which would further strengthen efforts to control and eliminate the disease.
- To identify further research needs in order to improve the chemotherapy and control of leprosy.

1.1 **WHO Study Group on Chemotherapy of Leprosy for Control Programmes, 1981**

When the WHO Study Group on Chemotherapy of Leprosy for Control Programmes met in 1981, leprosy control programmes faced a variety of serious constraints that not only threatened to hinder further progress but, left unchecked, could have resulted in a serious deterioration of the world leprosy situation. Widespread secondary dapsone resistance was being reported in up to 19% of patients previously treated with dapsone

¹ As of April 1994, it is estimated that over 5.6 million leprosy patients have been cured through MDT.

monotherapy. Of equal concern, primary dapsone resistance, mostly low degree, was being detected in some areas in as many as 50% of newly diagnosed, previously untreated cases (1). Furthermore, cases of resistance of *Mycobacterium leprae* to rifampicin and the thioamides had been reported among patients receiving these drugs as monotherapy. However, most control programmes had failed to appreciate the seriousness of the situation and thus had not implemented even the limited MDT regimens recommended in the fifth report of the WHO Expert Committee on Leprosy (2).

After reviewing the situation and data on the available drugs and from ongoing drug trials, the 1981 Study Group recommended that all leprosy patients (paucibacillary and multibacillary) be treated with regimens that would be effective in cases of dapsone resistance, but were also of relatively short duration. The recommended regimen for paucibacillary leprosy involved rifampicin and dapsone, administered for 6 months, while the regimen for multibacillary disease involved both these drugs, together with clofazimine, given for 24 months or until skin smears became negative. In addition, new simplified definitions of paucibacillary and multibacillary leprosy were introduced and operational guidelines were drawn up to help assure the successful implementation of the new regimens.

Within a few years these now standard WHO MDT regimens were widely implemented and the level of implementation has steadily increased over the past 12 years. The regimens have proved highly successful in preventing relapse. Indeed, the success of these regimens and the concurrent efforts by Member governments and nongovernmental organizations to strengthen leprosy control programmes led the World Health Assembly in 1991 to set a goal of elimination of leprosy as a public health problem (reducing the prevalence to below 1 per 10000 population) by the year 2000.

Although progress towards this goal has been excellent, it is appropriate at this time to review the chemotherapy of leprosy in the light of 12 years of experience with the current MDT regimens and the recent introduction of several new bactericidal antileprosy drugs.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30715

